Xencor, Inc. – Product Pipeline Review – 2012
Summary
Global Market Direct’s pharmaceuticals report, “Xencor, Inc. - Product Pipeline Review - 2012” provides data on the Xencor, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Xencor, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Xencor, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope
Current R&D Portfolio of Xencor, Inc.; Xencor, Inc. - Key Therapeutics; Xencor, Inc. - Pipeline Overview and Promising Molecules; Xencor, Inc. - News; Xencor, Inc. - Latest Updates; Xencor, Inc. - Pipeline; Xencor, Inc. - Discontinued/Dormant Projects
Summary
Global Market Direct’s pharmaceuticals report, “Xencor, Inc. - Product Pipeline Review - 2012” provides data on the Xencor, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Xencor, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Xencor, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope
- Xencor, Inc. - Brief Xencor, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Xencor, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Xencor, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Xencor, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
- Evaluate Xencor, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Xencor, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Xencor, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Xencor, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Xencor, Inc. and identify potential opportunities in those areas.
Current R&D Portfolio of Xencor, Inc.; Xencor, Inc. - Key Therapeutics; Xencor, Inc. - Pipeline Overview and Promising Molecules; Xencor, Inc. - News; Xencor, Inc. - Latest Updates; Xencor, Inc. - Pipeline; Xencor, Inc. - Discontinued/Dormant Projects
Xencor, Inc. Snapshot
Xencor, Inc. Overview
Key Information
Key Facts
Xencor, Inc. – Research and Development Overview
Key Therapeutic Areas
Xencor, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Xencor, Inc. – Pipeline Products Glance
Xencor, Inc. Clinical Stage Pipeline Products
Phase I Products/Combination Treatment Modalities
Xencor, Inc. – Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Xencor, Inc. – Drug Profiles
XmAb2513
Product Description
Mechanism of Action
R&D Progress
XmAb5485
Product Description
Mechanism of Action
R&D Progress
Xmab5592
Product Description
Mechanism of Action
R&D Progress
XmAb5871
Product Description
Mechanism of Action
R&D Progress
XmAb7195
Product Description
Mechanism of Action
R&D Progress
Xpro1595
Product Description
Mechanism of Action
R&D Progress
Xencor, Inc. – Pipeline Analysis
Xencor, Inc. – Pipeline Products by Therapeutic Class
Xencor, Inc. – Pipeline Products By Target
Xencor, Inc. – Pipeline Products By Mechanism of Action
Xencor, Inc. – Recent Pipeline Updates
Xencor, Inc. - Dormant Projects
Xencor, Inc. – Locations And Subsidiaries
Head Office
Financial Deals Landscape
Xencor, Inc., Deals Summary
Xencor, Inc., Pharmaceuticals & Healthcare, Deal Details
Venture Financing
Xencor Secures $7.5 Million In Venture Financing
Xencor Raises Additional $15 Million In Series E Financing
Xencor Completes $45 Million Venture Financing Round
Xencor Secures $6 Million In Bridge Financing
Xencor Raises $20 Million In Series D Financing
Partnerships
Xencor Enters Into Co-Development Agreement With Boehringer Ingelheim For Biosuperior Monoclonal Antibodies
Amgen Enters Into Co-Development Agreement With Xencor For XmAb5871
Human Genome Sciences Enters Into Collaboration With Xencor
Xencor Enters Into Co-Development Agreement With Eli Lilly
Licensing Agreements
Xencor Enters Into Licensing Agreement With Pfizer
Xencor Extends Licensing Agreement With Roche
Xencor Enters Into Licensing Agreement With Cambridge University
MorphoSys Enters Into Licensing Agreement With Xencor
Xencor Enters Into Licensing Agreement With Centocor For XmAb And Xtend Technology
Xencor Enters Into Licensing Agreement With Merck
Xencor Enters Into Licensing Agreement With CSL
Boehringer Ingelheim Enters Into Licensing Agreement With Xencor
Xencor Enters Into Licensing Agreement With Centocor For ImmunoFilter Technology
Xencor Enters Into Licensing Agreement With Eli Lilly and Company
MedImmune Enters Into An Agreement With Xencor
Arthron Enters Into Licensing Agreement With Xencor
Xencor Enters Into Licensing Agreement With Centocor
Xencor Enters Into Licensing Agreement With Eli Lilly
Chugai Pharma Signs Agreement With Xencor
Xencor Enters Into Licensing Agreement With Roche
Xencor Enters Into Licensing Agreement With Genentech
Xencor Enters Into Licensing Agreement With Protein Design Labs
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Xencor, Inc., Key Information
Xencor, Inc., Key Facts
Xencor, Inc. – Pipeline by Indication, 2012
Xencor, Inc. – Pipeline by Stage of Development, 2012
Xencor, Inc. – Monotherapy Products in Pipeline, 2012
Xencor, Inc. – Phase I, 2012
Xencor, Inc. – Pre-Clinical, 2012
Xencor, Inc. – Pipeline By Therapeutic Class, 2012
Xencor, Inc. - Pipeline By Target, 2012
Xencor, Inc. – Pipeline Products By Mechanism of Action, 2012
Xencor, Inc. – Recent Pipeline Updates, 2012
Xencor, Inc. - Dormant Developmental Projects,2012
Xencor, Inc., Deals Summary
Xencor Secures $7.5 Million In Venture Financing
Xencor Raises Additional $15 Million In Series E Financing
Xencor Completes $45 Million Venture Financing Round
Xencor Secures $6 Million In Bridge Financing
Xencor Raises $20 Million In Series D Financing
Xencor Enters Into Co-Development Agreement With Boehringer Ingelheim For Biosuperior Monoclonal Antibodies
Amgen Enters Into Co-Development Agreement With Xencor For XmAb5871
Human Genome Sciences Enters Into Collaboration With Xencor
Xencor Enters Into Co-Development Agreement With Eli Lilly
Xencor Enters Into Licensing Agreement With Pfizer
Xencor Extends Licensing Agreement With Roche
Xencor Enters Into Licensing Agreement With Cambridge University
MorphoSys Enters Into Licensing Agreement With Xencor
Xencor Enters Into Licensing Agreement With Centocor For XmAb And Xtend Technology
Xencor Enters Into Licensing Agreement With Merck
Xencor Enters Into Licensing Agreement With CSL
Boehringer Ingelheim Enters Into Licensing Agreement With Xencor
Xencor Enters Into Licensing Agreement With Centocor For ImmunoFilter Technology
Xencor Enters Into Licensing Agreement With Eli Lilly and Company
MedImmune Enters Into An Agreement With Xencor
Arthron Enters Into Licensing Agreement With Xencor
Xencor Enters Into Licensing Agreement With Centocor
Xencor Enters Into Licensing Agreement With Eli Lilly
Chugai Pharma Signs Agreement With Xencor
Xencor Enters Into Licensing Agreement With Roche
Xencor Enters Into Licensing Agreement With Genentech
Xencor Enters Into Licensing Agreement With Protein Design Labs
LIST OF FIGURES
Xencor, Inc. – Pipeline by Indication, 2012
Xencor, Inc. – Pipeline by Stage of Development, 2012
Xencor, Inc. – Monotherapy Products in Pipeline, 2012
Xencor, Inc. – Pipeline By Therapeutic Class, 2012
Xencor, Inc. - Pipeline By Target, 2012
Xencor, Inc. - Pipeline Products By Mechanism of Action, 2012
Xencor, Inc. Overview
Key Information
Key Facts
Xencor, Inc. – Research and Development Overview
Key Therapeutic Areas
Xencor, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Xencor, Inc. – Pipeline Products Glance
Xencor, Inc. Clinical Stage Pipeline Products
Phase I Products/Combination Treatment Modalities
Xencor, Inc. – Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Xencor, Inc. – Drug Profiles
XmAb2513
Product Description
Mechanism of Action
R&D Progress
XmAb5485
Product Description
Mechanism of Action
R&D Progress
Xmab5592
Product Description
Mechanism of Action
R&D Progress
XmAb5871
Product Description
Mechanism of Action
R&D Progress
XmAb7195
Product Description
Mechanism of Action
R&D Progress
Xpro1595
Product Description
Mechanism of Action
R&D Progress
Xencor, Inc. – Pipeline Analysis
Xencor, Inc. – Pipeline Products by Therapeutic Class
Xencor, Inc. – Pipeline Products By Target
Xencor, Inc. – Pipeline Products By Mechanism of Action
Xencor, Inc. – Recent Pipeline Updates
Xencor, Inc. - Dormant Projects
Xencor, Inc. – Locations And Subsidiaries
Head Office
Financial Deals Landscape
Xencor, Inc., Deals Summary
Xencor, Inc., Pharmaceuticals & Healthcare, Deal Details
Venture Financing
Xencor Secures $7.5 Million In Venture Financing
Xencor Raises Additional $15 Million In Series E Financing
Xencor Completes $45 Million Venture Financing Round
Xencor Secures $6 Million In Bridge Financing
Xencor Raises $20 Million In Series D Financing
Partnerships
Xencor Enters Into Co-Development Agreement With Boehringer Ingelheim For Biosuperior Monoclonal Antibodies
Amgen Enters Into Co-Development Agreement With Xencor For XmAb5871
Human Genome Sciences Enters Into Collaboration With Xencor
Xencor Enters Into Co-Development Agreement With Eli Lilly
Licensing Agreements
Xencor Enters Into Licensing Agreement With Pfizer
Xencor Extends Licensing Agreement With Roche
Xencor Enters Into Licensing Agreement With Cambridge University
MorphoSys Enters Into Licensing Agreement With Xencor
Xencor Enters Into Licensing Agreement With Centocor For XmAb And Xtend Technology
Xencor Enters Into Licensing Agreement With Merck
Xencor Enters Into Licensing Agreement With CSL
Boehringer Ingelheim Enters Into Licensing Agreement With Xencor
Xencor Enters Into Licensing Agreement With Centocor For ImmunoFilter Technology
Xencor Enters Into Licensing Agreement With Eli Lilly and Company
MedImmune Enters Into An Agreement With Xencor
Arthron Enters Into Licensing Agreement With Xencor
Xencor Enters Into Licensing Agreement With Centocor
Xencor Enters Into Licensing Agreement With Eli Lilly
Chugai Pharma Signs Agreement With Xencor
Xencor Enters Into Licensing Agreement With Roche
Xencor Enters Into Licensing Agreement With Genentech
Xencor Enters Into Licensing Agreement With Protein Design Labs
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Xencor, Inc., Key Information
Xencor, Inc., Key Facts
Xencor, Inc. – Pipeline by Indication, 2012
Xencor, Inc. – Pipeline by Stage of Development, 2012
Xencor, Inc. – Monotherapy Products in Pipeline, 2012
Xencor, Inc. – Phase I, 2012
Xencor, Inc. – Pre-Clinical, 2012
Xencor, Inc. – Pipeline By Therapeutic Class, 2012
Xencor, Inc. - Pipeline By Target, 2012
Xencor, Inc. – Pipeline Products By Mechanism of Action, 2012
Xencor, Inc. – Recent Pipeline Updates, 2012
Xencor, Inc. - Dormant Developmental Projects,2012
Xencor, Inc., Deals Summary
Xencor Secures $7.5 Million In Venture Financing
Xencor Raises Additional $15 Million In Series E Financing
Xencor Completes $45 Million Venture Financing Round
Xencor Secures $6 Million In Bridge Financing
Xencor Raises $20 Million In Series D Financing
Xencor Enters Into Co-Development Agreement With Boehringer Ingelheim For Biosuperior Monoclonal Antibodies
Amgen Enters Into Co-Development Agreement With Xencor For XmAb5871
Human Genome Sciences Enters Into Collaboration With Xencor
Xencor Enters Into Co-Development Agreement With Eli Lilly
Xencor Enters Into Licensing Agreement With Pfizer
Xencor Extends Licensing Agreement With Roche
Xencor Enters Into Licensing Agreement With Cambridge University
MorphoSys Enters Into Licensing Agreement With Xencor
Xencor Enters Into Licensing Agreement With Centocor For XmAb And Xtend Technology
Xencor Enters Into Licensing Agreement With Merck
Xencor Enters Into Licensing Agreement With CSL
Boehringer Ingelheim Enters Into Licensing Agreement With Xencor
Xencor Enters Into Licensing Agreement With Centocor For ImmunoFilter Technology
Xencor Enters Into Licensing Agreement With Eli Lilly and Company
MedImmune Enters Into An Agreement With Xencor
Arthron Enters Into Licensing Agreement With Xencor
Xencor Enters Into Licensing Agreement With Centocor
Xencor Enters Into Licensing Agreement With Eli Lilly
Chugai Pharma Signs Agreement With Xencor
Xencor Enters Into Licensing Agreement With Roche
Xencor Enters Into Licensing Agreement With Genentech
Xencor Enters Into Licensing Agreement With Protein Design Labs
LIST OF FIGURES
Xencor, Inc. – Pipeline by Indication, 2012
Xencor, Inc. – Pipeline by Stage of Development, 2012
Xencor, Inc. – Monotherapy Products in Pipeline, 2012
Xencor, Inc. – Pipeline By Therapeutic Class, 2012
Xencor, Inc. - Pipeline By Target, 2012
Xencor, Inc. - Pipeline Products By Mechanism of Action, 2012
